Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder

被引:16
作者
Edwards, J
Duncan, P
Going, JJ
Grigor, KM
Watters, AD
Bartlett, JMS
机构
[1] Univ Glasgow, Royal Infirm, Dept Surg, Glasgow G31 2ER, Lanark, Scotland
[2] Univ Glasgow, Royal Infirm, Dept Pathol, Glasgow G31 2ER, Lanark, Scotland
[3] Univ Edinburgh, Royal Edinburgh Infirm, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland
关键词
LOH; TCC of the urinary bladder; chromosome; 11; and; 17;
D O I
10.1054/bjoc.2001.2159
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Approximately 2/3 of patients diagnosed with superficial transitional cell carcinoma of the urinary bladder (TCC) will recur within 2 years. Loss of chromosome 9 and loss of heterozygosity (LOH) at 9q34 in index TCCs identify a subset of patients at high risk of recurrence. This study explores genetic alterations on chromosomes 4, 8, 11 and 17 as predictors of recurrence. A total of 109 carcinomas were investigated at 26 loci. DNA was extracted from microdissected archival normal/tumour tissue and was analysed for loss of heterozygosity (LOH). Fluorescent PCR was performed and genotyping carried out on a Perkin Elmer AB1377 sequencer. LOH of D11S490 or D17S928 was significantly more frequent in index carcinomas of patients who experienced recurrence compared to those with no recurrence (P = 0.004 and 0.019 respectively). These results suggest that loss of these regions is associated with recurrence of TCC. Further investigation is required to identify genes in these regions, which might be responsible for driving recurrence in TCC of the urinary bladder. (C) 2001 Cancer Research Campaign.
引用
收藏
页码:1894 / 1899
页数:6
相关论文
共 51 条
[41]  
Simon R, 1998, J PATHOL, V185, P345
[42]  
SPRUCK CH, 1994, CANCER RES, V54, P784
[43]  
THEILE M, 1995, ONCOGENE, V10, P439
[44]  
Tsutsumi M, 1997, Int J Urol, V4, P74, DOI 10.1111/j.1442-2042.1997.tb00144.x
[45]   Bladder cancer [J].
van der Meijden, APM .
BMJ-BRITISH MEDICAL JOURNAL, 1998, 317 (7169) :1366-1369
[46]  
Voorter CEM, 1996, INT J CANCER, V65, P301, DOI 10.1002/(SICI)1097-0215(19960126)65:3<301::AID-IJC4>3.0.CO
[47]  
2-3
[48]  
Wagner U, 1999, J PATHOL, V188, P44, DOI 10.1002/(SICI)1096-9896(199905)188:1<44::AID-PATH320>3.0.CO
[49]  
2-Q
[50]  
Wagner U, 1997, AM J PATHOL, V151, P753